Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was upgraded by research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday.

Several other analysts have also recently commented on the company. Dawson James restated a “buy” rating and issued a $9.00 target price on shares of Tonix Pharmaceuticals Holding Corp. in a research report on Wednesday, August 23rd. Drexel Hamilton began coverage on Tonix Pharmaceuticals Holding Corp. in a research report on Tuesday, August 22nd. They issued a “buy” rating on the stock. Roth Capital upgraded Tonix Pharmaceuticals Holding Corp. from a “neutral” rating to a “buy” rating and set a $6.00 target price on the stock in a research report on Friday, August 18th. They noted that the move was a valuation call. Finally, Aegis began coverage on Tonix Pharmaceuticals Holding Corp. in a research report on Monday, June 26th. They issued a “buy” rating and a $10.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. Tonix Pharmaceuticals Holding Corp. currently has a consensus rating of “Hold” and an average target price of $8.33.

Tonix Pharmaceuticals Holding Corp. (TNXP) traded up 2.39% on Friday, hitting $3.86. The stock had a trading volume of 49,916 shares. The company’s market cap is $28.98 million. Tonix Pharmaceuticals Holding Corp. has a 12-month low of $2.85 and a 12-month high of $27.50. The company’s 50 day moving average price is $3.68 and its 200-day moving average price is $3.51.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last posted its earnings results on Monday, August 14th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.13. Equities research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post ($3.02) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Tonix Pharmaceuticals Holding Corp. (TNXP) Upgraded by ValuEngine to Sell” was originally published by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.watchlistnews.com/tonix-pharmaceuticals-holding-corp-tnxp-upgraded-by-valuengine-to-sell/1536920.html.

In other news, Director Ernest Mario sold 6,105 shares of the firm’s stock in a transaction on Friday, June 30th. The stock was sold at an average price of $4.28, for a total transaction of $26,129.40. Following the completion of the sale, the director now directly owns 63,073 shares of the company’s stock, valued at approximately $269,952.44. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Seth Lederman acquired 20,000 shares of Tonix Pharmaceuticals Holding Corp. stock in a transaction dated Tuesday, June 20th. The shares were bought at an average cost of $4.22 per share, with a total value of $84,400.00. Following the completion of the purchase, the chief executive officer now owns 7,912 shares in the company, valued at $33,388.64. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 50,000 shares of company stock valued at $188,050. Corporate insiders own 4.00% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC bought a new stake in Tonix Pharmaceuticals Holding Corp. during the first quarter valued at $119,000. Dialectic Capital Management LP bought a new stake in Tonix Pharmaceuticals Holding Corp. during the first quarter valued at $187,000. Vanguard Group Inc. raised its stake in Tonix Pharmaceuticals Holding Corp. by 28.8% in the second quarter. Vanguard Group Inc. now owns 184,377 shares of the company’s stock valued at $799,000 after buying an additional 41,264 shares in the last quarter. B. Riley Financial Inc. bought a new stake in Tonix Pharmaceuticals Holding Corp. during the second quarter valued at $1,637,000. Finally, Renaissance Technologies LLC raised its stake in Tonix Pharmaceuticals Holding Corp. by 108.4% in the fourth quarter. Renaissance Technologies LLC now owns 774,603 shares of the company’s stock valued at $364,000 after buying an additional 402,898 shares in the last quarter. 23.76% of the stock is owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Holding Corp. Company Profile

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

Analyst Recommendations for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Receive News & Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.